Evidence map›Paper›PMID 31317218›Full record

ArticleCancer immunology, immunotherapy : CII2019

Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.

Jun Zhou, Jingjing Li, Indira Guleria, Tianqi Chen, Anita Giobbie-Hurder, Jonathan Stevens, Meghna Gupta, Xinqi Wu, Ryan C Brennick, Michael P Manos and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. The role ofTranslational cancer research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jun ZhouDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jingjing LiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Indira GuleriaTissue Typing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Tianqi ChenDivision of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Anita Giobbie-HurderCenter for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jonathan StevensTissue Typing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Meghna GuptaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Xinqi WuDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Ryan C BrennickDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Michael P ManosDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
F Stephen HodiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. stephen_hodi@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-6825-091X
Harvard University · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · US

Funding

Cancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4M
NCI NIH HHS U24 CA224331
6 · The paper itself

Abstract

Expression of inhibitors of apoptosis protein (IAP) family members is associated with poor prognosis in cancer patients. Immunity to ML-IAP (livin) and survivin has been well studied in patients with a variety of tumors. XIAP, the most potent inhibitor of apoptosis, is widely expressed in melanoma. To better define its potential role as an immunogenic target, cellular and humoral responses to XIAP were investigated in patients with advanced melanoma. An overlapping peptide library covering the full length of the XIAP protein was used to screen T cell responses of peripheral blood mononuclear cells (PBMC) from stage-IV melanoma patients treated with or without anti-CTLA4 (ipilimumab). The screen identified an array of peptides that predominantly induced CD4

Indexed as

Antineoplastic AgentsCD4-Positive T-LymphocytesCell ProliferationCells, CulturedEnzyme-Linked Immunospot AssayEpitopes, T-LymphocyteHumansImmunity, HumoralImmunotherapyIpilimumabLymphocyte ActivationMelanomaNeoplasm StagingPeptide FragmentsSkin NeoplasmsTreatment OutcomeAntineoplastic AgentsEpitopes, T-LymphocyteIpilimumabPeptide FragmentsXIAP protein, humanX-Linked Inhibitor of Apoptosis ProteinCTLA4 blockadeMelanomaPD-1 blockadeXIAP

Identifiers

PMID31317218
PMCPMC6684401
OpenAlexW2958195666

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.